Children with cow’s milk allergies may be hypersensitive to the a-lactalbumin-containing Sabin vaccine.

PMID: 

Clin Exp Allergy. 2013 Feb ;43(2):249-54. PMID: 23331566

Abstract Title: 

Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy.

Abstract: 

BACKGROUND: The Sabin vaccine is used world-wide, and most children with food allergies receive it without incident. However, in the 2009 vaccination campaign conducted in Argentina, four children experienced immediate-type hypersensitivity reactions following vaccination.OBJECTIVE: We aimed to review the medical history of the affected children, study their allergic condition after the episodes and analyse the presence of allergenic vaccine components.METHODS: Patients were selected based on their immediate allergic reactions following vaccination. They were assessed for allergies to cow's milk and hen's egg. The presence of cow's milk proteins in the vaccine was tested by various immunoassays involving cow's milk- orα-lactalbumin-specific polyclonal rabbit antiserum and patient sera.RESULTS: All of the patients had a history of milk allergy, and no history or current evidence of egg hypersensitivity was found. Levels of cow's milk- and Sabin vaccine-specific IgE were increased, and the result of a skin prick test with cow's milk proteins or the Sabin vaccine was positive in each patient. In addition, an ELISA using specific rabbit antiserum detectedα-lactalbumin in the Sabin vaccine. When α-lactalbumin was employed as a soluble inhibitor in a competitive ELISA, binding to vaccine-coated plates by cow's milk- or α-lactalbumin-specific rabbit antiserum or by patient serum containing IgE was inhibited.CONCLUSIONS: We have demonstrated that these patients were allergic to cow's milk, and had circulating and mast cell-bound IgE antibodies specific to cow's milk proteins. We found that the Sabin vaccine containedα-lactalbumin, which may have been responsible for the reactions elicited following vaccination with the Sabin and dual viral vaccines in combination.

read more

Both the inactivated polio virus vaccine and the oral polio virus vaccine create the risk of vaccine-related polio. What do they really solve?

PMID: 

N Engl J Med. 2014 Oct 16 ;371(16):1476-9. PMID: 25317869

Abstract Title: 

Achieving and maintaining polio eradication–new strategies.

Abstract: 

[n/a]

read more

Evidence of significant conflicts of interest in vaccine research.

PMID: 

Vaccine. 2015 May 21 ;33(22):2594-601. Epub 2015 Apr 14. PMID: 25882172

Abstract Title: 

Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.

Abstract: 

BACKGROUND: Pertussis in adults and adolescents could be reduced by replacing traditional tetanus and diphtheria (Td) boosters with reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccines. This study evaluated the administration of dTpa-IPV (dTpa-inactivated poliovirus) in adults ten years after they received a booster dose of either dTpa-IPV, dTpa+IPV or Td-IPV in trial NCT01277705.METHODS: Open multicentre, phase IV study (https://ift.tt/2tnKPsI) in which healthy adults, who had received a previous dose of dTpa-IPV, dTpa+IPV or Td-IPV ten years earlier, received a single decennial booster dose of dTpa-IPV (Boostrix-polio, GlaxoSmithKline Vaccines). Blood samples were collected before and one month after booster vaccination. Antibody concentrations against all vaccine antigens were measured and reactogenicity and safety were assessed.RESULTS: A total of 211 subjects (mean age 50.3 years) received vaccination of whom 201 were included in the according-to-protocol cohort for immunogenicity. Before the decennial dTpa-IPV booster,≥71.0% subjects were seroprotected/seropositive against all vaccine antigens. One month after the booster dose, all subjects were seroprotected against tetanus and poliovirus types 2 and 3; ≥95.7% subjects were seroprotected against diphtheria and ≥98.3% against poliovirus type 1. Anti-pertussis booster responses for the various antigens were observed in ≥76.5% (pertussis toxoid; PT), ≥85.1% (filamentous haemagglutinin; FHA) and ≥63.2% (pertactin; PRN) of subjects. During the 4-day follow-up, the overall incidence of local AEs was 71.6%, 75.0% and 72.2% in dTpa-IPV, dTpa+IPV and Td-IPV groups, respectively. Pain was the most frequent solicited local adverse event (AE; ≥62.7% subjects) and fatigue the most frequent solicited general AE (≥18.5%). No serious AEs were reported during the study.CONCLUSION: A booster dose of dTpa-IPV was immunogenic and well tolerated in adults who had received a booster dose of either dTpa-IPV, dTpa+IPV or Td-IPV, ten years previously and supports the repeated administration of dTpa-IPV.

read more

Concern remains whether immunity induced by a single IPV dose will prevent the emergence of circulating vaccine-derived type-2 poliovirus after removal of Sabin type-2 virus.

PMID: 

Clin Infect Dis. 2018 10 30 ;67(suppl_1):S35-S41. PMID: 30376081

Abstract Title: 

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.

Abstract: 

In May 2016, countries using oral polio vaccine for routine immunization switched from trivalent oral poliovirus vaccine (tOPV) to bivalent type 1 and 3 OPV (bOPV). This was done in order to reduce risks from type 2 vaccine-derived polioviruses (VDPV2) and vaccine-associated paralytic poliomyelitis (VAPP) and to introduce≥1 dose of inactivated poliovirus vaccine (IPV) to mitigate post-switch loss of type 2 immunity. We conducted a literature review of studies that assessed humoral and intestinal immunogenicity induced by the newly recommended schedules. Differences in seroconversion rates were closely associated with both timing of first IPV administration and number of doses administered. All studies demonstrated high levels of immunity for types 1 and 3 regardless of immunization schedule. When administered late in the primary series, a second dose of IPV closed the humoral immunity gap against polio type2 associated with a single dose. IPV doses and administration schedules appear to have limited impact on type 2 excretion following challenge.

read more

Case report of bursitis and bone erosion caused by the DTP vaccine.

PMID: 

Vaccine. 2015 Nov 17 ;33(46):6152-5. Epub 2015 Oct 11. PMID: 26458794

Abstract Title: 

Bone erosion and subacromial bursitis caused by diphtheria-tetanus-poliomyelitis vaccine.

Abstract: 

Revaxis(®) is a vaccine against diphtheria, tetanus and poliomyelitis (dT-IPV). This vaccine should not be administered by the intradermal or intravenous route. Poor injection techniques and related consequences are rare. We report a case of bursitis associated with reactive glenohumeral effusion complicated by bone erosion occurring after injection of the dT-IPV vaccine. A 26 year old patient was admitted for painful left shoulder causing functional impairment. Control magnetic resonance imaging showed bone oedema on the upper outer part of the humeral head, with a slight cortical irregularity, indicating that the vaccine was injected in contact with the bone at this location, causing erosion. Outcome was favourable after intra-articular corticosteroids. Reports of articular or periarticular injury after vaccination are extremely rare, in view of the substantial number of vaccines administeredevery year. The potential complications of vaccination are well known to general practitioners but under-reported in the literature.

read more

Attentuated Sabin poliovirus strains are being developed due to the chances that the current highly virulent strain may be released from production facilities. However, it’s well-known that Sabin strains may revert to paralytic strains.

PMID: 

PLoS Pathog. 2015 Dec ;11(12):e1005316. Epub 2015 Dec 31. PMID: 26720150

Abstract Title: 

New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.

Abstract: 

Poliomyelitis has nearly been eradicated through the efforts of the World Health Organization's Global Eradication Initiative raising questions on containment of the virus after it has been eliminated in the wild. Most manufacture of inactivated polio vaccines currently requires the growth of large amounts of highly virulent poliovirus, and release from a production facility after eradication could be disastrous; WHO have therefore recommended the use of the attenuated Sabin strains for production as a safer option although it is recognised that they can revert to a transmissible paralytic form. We have exploited the understanding of the molecular virology of the Sabin vaccine strains to design viruses that are extremely genetically stable and hyperattenuated. The viruses are based on the type 3 Sabin vaccine strain and have been genetically modified in domain V of the 5' non-coding region by changing base pairs to produce a cassette into which capsid regions of other serotypes have been introduced. The viruses give satisfactory yields of antigenically and immunogenically correct viruses in culture, are without measurable neurovirulence and fail to infect non-human primates under conditions where the Sabin strains will do so.

read more

Replacement of OPV with IPV could translate to approximately 4000 deaths for each case of vaccine-associated paralytic poliomyelitis prevented, and might cause more than 300,000 additional deaths each year.

PMID: 

Lancet. 2016 Mar 12 ;387(10023):1054-1055. PMID: 27025182

Abstract Title: 

Changing oral vaccine to inactivated polio vaccine might increase mortality.

Abstract: 

[n/a]

read more

It remains to be assessed whether IPV has non-specific effects and especially whether IPV could be detrimental for child health.

PMID: 

Lancet Infect Dis. 2016 Apr ;16(4):410. PMID: 27036345

Abstract Title: 

Is introduction of IPV"Good news for billions of children"?–Author's reply.

Abstract: 

[n/a]

read more

Further evidence of poorly designed vaccine clinical trials to investigate safety.

PMID: 

Vaccine. 2016 07 19 ;34(33):3810-6. Epub 2016 Jun 18. PMID: 27288217

Abstract Title: 

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

Abstract: 

BACKGROUND: Combination vaccines simplify vaccination visits and improve coverage and timeliness. DTaP5-HB-IPV-Hib is a new investigational, fully-liquid, combination vaccine designed to protect against 6 infectious diseases, including 5 pertussis antigens and OMPC instead of PT as conjugated protein for Hib component.METHODS: In this multicenter, double-blind, comparator-controlled, Phase III study (NCT01480258) conducted in Sweden, Italy, and Finland, healthy infants were randomized 1:1 to receive one two immunization regimens. The DTaP5-HB-IPV-Hib Group received the investigational hexavalent vaccine (DTaP5-HB-IPV-Hib) and the Control Group received Infanrix-hexa (DTPa3-HBV-IPV/Hib) at 2, 4 and 11-12months of age. Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) or Rotarix (RV1) at 2, 4months of age and PCV13 at 11-12months. Subjects administered RV5 received a 3rd dose at 5months of age.RESULTS: A total of 656 subjects were randomized to the DTaP5-HB-IPV-Hib Group and 659 subjects to Control Group. Immune responses to all vaccine antigens post-toddler dose were non-inferior in the DTaP5-HB-IPV-Hib Group as compared to the Control Group. Additionally, the post-dose 2 and pre-toddler DTaP5-HB-IPV-Hib anti-PRP responses were superior. The DTaP5-HB-IPV-Hib Group responses to concomitant RV1 were non-inferior compared to the Control Group. Solicited adverse event rates after any dose were similar in both groups, except for higher rates of pyrexia (6.4% difference; 95% CI: 1.5,11.3) and somnolence (5.8% difference; 95% CI: 1.7,9.8) in the DTaP5-HB-IPV-Hib Group. Vaccine-related serious adverse events occurred infrequently in the DTaP5-HB-IPV-Hib Group (0.3%) and the Control Group (0.5%).CONCLUSIONS: The safety and immunogenicity of DTaP5-HB-IPV-Hib is generally comparable to Control when administered in the 2, 4, 11-12month schedule. Early Hib responses were superior versus Control. DTaP5-HB-IPV-Hib could provide a new hexavalent option for pediatric combination vaccines, aligned with recommended immunizations in Europe.STUDY IDENTIFICATION: V419-008 CLINICALTRIALS.GOV identifier: NCT01480258.

read more

Ambient fine particulate matter induces inflammatory responses of vascular endothelial cells.

PMID: 

Toxicol Ind Health. 2019 Oct ;35(10):670-678. Epub 2019 Oct 10. PMID: 31601156

Abstract Title: 

Ambient fine particulate matter induces inflammatory responses of vascular endothelial cells through activating TLR-mediated pathway.

Abstract: 

This study aims to investigate the role of Toll-like receptors (TLRs) on fine particulate matter (PM)-induced inflammatory responses of vascular endothelial cells. Inflammatory factors and TLRs were examined in the aorta of mice after nonsurgical intratracheal instillation of PMas well as in the human umbilical vein endothelial cells (HUVECs) treated with PM. In addition, the effects of TLR2 and TLR4 inhibitors in the secretion of interleukin 6 (IL-6) and IL-1β and the expression of TLRs were determined in the HUVECs. The results showed that PMcould increase the expression of IL-1β, IL-6, TLR2, and TLR4and. Anti-TLR2 IgG or TAK242, an inhibitor of TLR4, decreased the secretion of IL-1β and IL-6 by HUVECs and reduced the expression of corresponding TLRs. In conclusion, we demonstrate that both TLR2 and TLR4 are involved in PM-induced inflammatory responses of vascular endothelial cells. Inhibition of TLR2 and TLR4 expression has the potential to prevent PM-induced cardiovascular diseases.

read more

Design a site like this with WordPress.com
Get started